Development of Assays for Detecting Significant Prostate Cancer Based on Molecular Alterations Associated with Cancer in Non-Neoplastic Prostate Tissue
Abstract
The goal of this project is to develop biopsy based assays to assess the probability that patients with a negative biopsy or with a prostate cancer (CaP) Gleason score 6 (GS6) biopsy actually have "significant" CaP of Gleason score 7 or higher which was missed during the biopsy evaluations due to insufficient sampling. Experimental design includes discovery and validation steps. In the discovery step, we have generated a sizable set of close to 200 gene expression and methylation sequencing data from High grade PIN (HGPIN) collected by laser captured microdissection (LCM) and bulk normal samples. Our data set was further boosted through collaboration with another Mayo investigator. Through an RFA by the Mayo Clinomics Program, we completed gene expression and methylation sequencing of indolent and significant tumor samples (ca. 60 totals). Based on our previous experience, genomic profiles of tumor can provide crucial clues in field effect biomarker selection and therefore we anticipate these data will be important in the success of this project. We are very close to the completion of collecting RNA/DNA from the FFPE samples in the validation step. We expect that in the coming year we will be able to validate our findings in the discovery step and develop biopsy based models that will be useful in clinical settings.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2015
- Accession Number
- ADA626548
Entities
People
- Farhad Kosari
- G. Vasmatzis
- J. C. Cheville
- M. Manemann
- R. J. Karnes
- S. J. Murphy
Organizations
- Mayo Clinic